Selinger CP, Lenti MV, De Silvestri A. Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply. Aliment Pharmacol Ther 2022;55:1070-1071.
PMID: 35362123